STOCK TITAN

Voyager Therapeutics Inc - VYGR STOCK NEWS

Welcome to our dedicated page for Voyager Therapeutics news (Ticker: VYGR), a resource for investors and traders seeking the latest updates and insights on Voyager Therapeutics stock.

Overview

Voyager Therapeutics Inc (VYGR) is a biotechnology company focused on developing innovative gene therapies for severe and debilitating diseases of the central nervous system (CNS). Using advanced AAV gene therapy techniques and its proprietary TRACER™ capsid discovery platform, Voyager is dedicated to overcoming traditional barriers in gene delivery and creating transformative solutions for neurological disorders.

Core Technology and Platform

The company leverages its TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) platform to engineer and optimize novel AAV capsids that are designed to cross the blood-brain barrier with high efficiency. This RNA-based screening enables rapid identification of capsid variants with enhanced CNS tropism and controlled tissue targeting, ensuring robust genetic payload delivery to areas of the brain traditionally hard to reach. The platform underpins both its gene therapy and antibody development programs, reflecting a robust integration of genetic science and neuroscience.

Pipeline and Disease Focus

Voyager Therapeutics maintains an extensive pipeline of programs aimed at addressing several critical CNS diseases. The company is developing gene therapy candidates to target conditions such as Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia. Additionally, Voyager is advancing therapies aimed at modifying the pathological processes in Alzheimer’s disease through tau silencing and anti-tau antibodies. Each candidate is carefully designed to modulate protein expression in the CNS, aiming to slow disease progression and improve patient outcomes.

Research and Development Approach

Emphasizing rigorous process development and production scalability, Voyager invests heavily in vector optimization and sophisticated dosing techniques. The company conducts cross-species preclinical studies to ensure that its TRACER-generated capsids achieve widespread and efficient gene expression while minimizing off-target effects. Its commitment to scientific excellence is reflected in its strategic external collaborations, which not only validate its technology but also extend its reach within the neurogenetic medicines field.

Industry Significance and Competitive Position

Voyager Therapeutics distinguishes itself within the biotechnology landscape through its specialized focus on CNS diseases and its innovative AAV-based gene therapy solutions. By integrating cutting-edge gene editing methodologies with deep neuroscientific insights, the company fills a significant unmet need in neurological drug development. Its collaboration with established industry partners further underscores the scientific reliability, stringent development standards, and translational potential of its candidates. The company’s balanced portfolio and technology-driven approach position it as a critical contributor to the evolution of gene therapies for challenging neurological conditions.

Commitment to Innovation and Patient Impact

At the heart of Voyager Therapeutics’ mission is the goal of modifying the course of devastating neurological diseases. By focusing on durable gene expression attainable through a single administration, the company aims to provide long-lasting therapeutic benefits that can transform the quality of life for patients. Its efforts in process development and clinical standardization continue to set benchmarks within the field, reflecting a commitment to excellence that is both scientifically robust and patient-centered.

This comprehensive approach—encompassing advanced vector engineering, strategic collaborations, and meticulous clinical development—underscores Voyager Therapeutics’ prominence in the realm of neurogenetic medicines and offers a detailed perspective for investors and industry observers alike.

Rhea-AI Summary
Voyager Therapeutics, Inc. reported strong financial results for Q4 2023 and full year 2023, with approximately $431 million in pro-forma cash as of December 31, 2023. The company achieved key milestones, including strategic collaborations with Novartis and Neurocrine Biosciences. Voyager expects to advance multiple programs into the clinic by the end of next year, with a focus on gene therapy programs for diseases like Alzheimer's and ALS. The company's cash position and anticipated milestones provide runway into 2027, supporting the generation of clinical data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.25%
Tags
-
Rhea-AI Summary
Voyager Therapeutics, Inc. announces the selection of a lead development candidate in the Friedreich’s ataxia program in collaboration with Neurocrine Biosciences. The candidate combines a frataxin gene replacement payload with a novel capsid derived from Voyager’s TRACER platform. The program is expected to enter first-in-human clinical trials in 2025, triggering a $5 million milestone payment to Voyager. Voyager could receive additional milestone payments based on program advancement. The strategic collaboration aims to address the challenging FA disease through gene therapy, with potential milestone payments of up to $1.3 billion for Voyager.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.62%
Tags
none
-
Rhea-AI Summary
Voyager Therapeutics, Inc. (Nasdaq: VYGR) will report Q4 2023 financial results on Feb 28, 2024. A conference call and webcast will follow to review the results. Participants can register in advance to join the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
Rhea-AI Summary
Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced new data on VY-TAU01, their lead anti-tau antibody, and tau silencing gene therapy program for Alzheimer's disease treatment. The data, to be presented at AD/PD™ 2024, show promising results in non-human primates and mice. Voyager plans to file an IND for VY-TAU01 in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
none
-
Rhea-AI Summary
Voyager Therapeutics, Inc. will present at the Oppenheimer Life Sciences Conference on February 14, 2024. The webcast of the presentation can be accessed from the Investors section of Voyager's website. Chief Financial Officer Peter Pfreundschuh will be presenting at 11:20 a.m. ET. A replay of the webcast will be available on the company's website for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
conferences
-
Rhea-AI Summary
Voyager Therapeutics, Inc. (Nasdaq: VYGR) announces the pricing of an underwritten public offering of 7,777,778 shares of its common stock at a public offering price of $9.00 per share, and pre-funded warrants to purchase an aggregate of 3,333,333 shares of common stock at a public offering price of $8.999 per pre-funded warrant, for aggregate gross proceeds of approximately $100 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.36%
Tags
Rhea-AI Summary
Voyager Therapeutics, Inc. (Nasdaq: VYGR) has announced a public offering of $100 million of shares of its common stock. The company also expects to grant the underwriters a 30-day option to purchase up to an additional $15 million of shares. The net proceeds will be used for advancing its neurogenetic medicines and various clinical and preclinical development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.36%
Tags
-
Rhea-AI Summary
Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced CEO Alfred W. Sandrock, Jr., M.D., Ph.D., will present at the 42nd Annual J.P. Morgan Healthcare Conference. The webcast can be accessed from the Investors section of Voyager’s website, with a replay available for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.67%
Tags
conferences
-
Rhea-AI Summary
Voyager Therapeutics, Inc. (Nasdaq: VYGR) announces a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS) to advance potential gene therapies for Huntington’s disease (HD) and spinal muscular atrophy (SMA). Voyager will receive $100 million up-front and is eligible for up to $1.2 billion in milestone payments and tiered royalties. Novartis will pay Voyager $100 million, including a $20 million purchase of newly issued equity, and is eligible to receive milestone payments and tiered royalties on global net sales of products incorporating Voyager’s TRACER capsids.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.64%
Tags
none
Rhea-AI Summary
Voyager Therapeutics, Inc. (Nasdaq: VYGR) has announced the selection of a lead development candidate for its superoxide dismutase 1 (SOD1)-mutated amyotrophic lateral sclerosis (ALS) gene therapy program. The company anticipates filing an investigational new drug (IND) application with the FDA for the candidate in mid-2025. The candidate has shown a 73% reduction of SOD1 in cervical spinal cord motor neurons in a non-human primate study, with an ability to transduce both neurons and astrocytes. Data previously shared at the 2022 ASGCT annual meeting demonstrated an increase in survival by a median of 152 days in a G93A mouse model.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
none

FAQ

What is the current stock price of Voyager Therapeutics (VYGR)?

The current stock price of Voyager Therapeutics (VYGR) is $3.37 as of April 1, 2025.

What is the market cap of Voyager Therapeutics (VYGR)?

The market cap of Voyager Therapeutics (VYGR) is approximately 185.2M.

What is the primary focus of Voyager Therapeutics?

Voyager Therapeutics is dedicated to developing gene therapies for severe neurological diseases using innovative AAV platforms and advanced vector engineering.

What is the TRACER™ platform?

The TRACER™ platform is an RNA-based screening technology that enables rapid discovery and optimization of AAV capsids for improved blood-brain barrier penetration and targeted CNS delivery.

Which central nervous system diseases does Voyager address?

Voyager’s pipeline includes therapies for Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, and Alzheimer’s disease, among other CNS conditions.

How does Voyager’s technology enhance gene delivery to the brain?

Their engineered AAV capsids are designed to cross the blood-brain barrier efficiently, target specific cell types, and achieve robust gene expression while limiting off-target transduction.

What distinguishes Voyager Therapeutics from other biotech companies?

Voyager is distinguished by its specialized focus on CNS diseases, its proprietary TRACER™ capsid discovery platform, and its commitment to integrating advanced gene therapy approaches with deep neuroscientific expertise.

Does Voyager collaborate with other organizations?

Yes, Voyager has strategic collaborations with established biotech firms, enhancing the scientific rigor and translational impact of its gene therapy candidates.

How do Voyager's therapies aim to impact patient treatment?

Their gene therapy candidates are designed to modify the underlying disease mechanisms by regulating protein expression, potentially slowing disease progression and improving patient quality of life.

What research methods support Voyager's development approach?

Voyager employs cross-species preclinical studies, advanced vector optimization, and robust process development to validate the safety and efficacy of its therapies.
Voyager Therapeutics Inc

Nasdaq:VYGR

VYGR Rankings

VYGR Stock Data

185.22M
45.58M
17%
63.9%
4.95%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
LEXINGTON